Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Ezumi

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Studies in Health Technology and Informatics|December 8, 1997
3D and 4D atlas system of living human body structureN Suzuki, A Takatsu, A Hattori, et al.
Studies in Health Technology and Informatics|December 8, 1997
Simulator for virtual surgery using deformable organ models and force feedback systemN Suzuki, A Hattori, T Ezumi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2024
A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)H Sakai, J Tsurutani, Y Ozaki, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Studies in Health Technology and Informatics|December 8, 1997
3D and 4D atlas system of living human body structureN Suzuki, A Takatsu, A Hattori, et al.
Studies in Health Technology and Informatics|December 8, 1997
Simulator for virtual surgery using deformable organ models and force feedback systemN Suzuki, A Hattori, T Ezumi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2024
A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)H Sakai, J Tsurutani, Y Ozaki, et al.
Pageof 1